CN122103354A - 用于癌症治疗的多特异性结合蛋白 - Google Patents

用于癌症治疗的多特异性结合蛋白

Info

Publication number
CN122103354A
CN122103354A CN202511886140.8A CN202511886140A CN122103354A CN 122103354 A CN122103354 A CN 122103354A CN 202511886140 A CN202511886140 A CN 202511886140A CN 122103354 A CN122103354 A CN 122103354A
Authority
CN
China
Prior art keywords
seq
cdr
amino acid
acid sequence
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511886140.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·希普
P·亚当
M·吉列夫斯基
R·加内桑
P·N·戈尔曼
P·古普塔
M·拉莎诺
J·M·舍尔
V·H·沃伊诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN122103354(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN122103354A publication Critical patent/CN122103354A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202511886140.8A 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白 Pending CN122103354A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19201200.3 2019-10-02
EP19201200 2019-10-02
CN202080068909.4A CN114641496B (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
PCT/EP2020/077586 WO2021064137A2 (en) 2019-10-02 2020-10-01 Multi-specific binding proteins for cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080068909.4A Division CN114641496B (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白

Publications (1)

Publication Number Publication Date
CN122103354A true CN122103354A (zh) 2026-05-29

Family

ID=68136317

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202511886140.8A Pending CN122103354A (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
CN202511907124.2A Pending CN122277744A (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
CN202080068909.4A Active CN114641496B (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
CN202511896772.2A Pending CN122080223A (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202511907124.2A Pending CN122277744A (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
CN202080068909.4A Active CN114641496B (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白
CN202511896772.2A Pending CN122080223A (zh) 2019-10-02 2020-10-01 用于癌症治疗的多特异性结合蛋白

Country Status (24)

Country Link
US (2) US11732045B2 (cg-RX-API-DMAC7.html)
EP (1) EP4038100A2 (cg-RX-API-DMAC7.html)
JP (2) JP7387885B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220075383A (cg-RX-API-DMAC7.html)
CN (4) CN122103354A (cg-RX-API-DMAC7.html)
AR (1) AR120138A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020358893A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022004047A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153372A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000664A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003552A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220136A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000060A (cg-RX-API-DMAC7.html)
EC (1) ECSP22019193A (cg-RX-API-DMAC7.html)
IL (1) IL291817A (cg-RX-API-DMAC7.html)
JO (1) JOP20220079A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004042A (cg-RX-API-DMAC7.html)
MY (1) MY209387A (cg-RX-API-DMAC7.html)
PE (1) PE20221412A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550693A1 (cg-RX-API-DMAC7.html)
SA (1) SA522432139B1 (cg-RX-API-DMAC7.html)
TW (1) TWI878355B (cg-RX-API-DMAC7.html)
UA (1) UA130106C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021064137A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
AU2023370123A1 (en) 2022-10-26 2025-04-17 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994003678A1 (en) 1992-08-10 1994-02-17 Alcan Aluminium Uk Limited Fence
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
FI20090280L (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
CN104395344B (zh) * 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN114634569B (zh) * 2016-04-15 2024-08-20 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
WO2021064137A2 (en) 2021-04-08
PE20221412A1 (es) 2022-09-20
CN122277744A (zh) 2026-06-26
CN114641496A (zh) 2022-06-17
AR120138A1 (es) 2022-02-02
TW202128756A (zh) 2021-08-01
CA3153372A1 (en) 2021-04-08
JP7809680B2 (ja) 2026-02-02
JOP20220079A1 (ar) 2023-01-30
TWI878355B (zh) 2025-04-01
JP7387885B2 (ja) 2023-11-28
ECSP22019193A (es) 2022-04-29
CN122080223A (zh) 2026-05-26
US20230340130A1 (en) 2023-10-26
JP2024020414A (ja) 2024-02-14
UA130106C2 (uk) 2025-11-12
US11732045B2 (en) 2023-08-22
MX2022004042A (es) 2022-05-02
BR112022004047A2 (pt) 2022-05-24
SA522432139B1 (ar) 2024-08-29
CO2022003552A2 (es) 2022-04-19
CN114641496B (zh) 2026-01-02
EP4038100A2 (en) 2022-08-10
DOP2022000060A (es) 2022-05-31
JP2022551081A (ja) 2022-12-07
CL2022000664A1 (es) 2023-01-06
US20210107983A1 (en) 2021-04-15
CR20220136A (es) 2022-05-27
KR20220075383A (ko) 2022-06-08
MY209387A (en) 2025-07-07
AU2020358893A1 (en) 2022-03-31
WO2021064137A3 (en) 2021-05-14
PH12022550693A1 (en) 2023-03-27
IL291817A (en) 2022-06-01

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination